Patents Assigned to Saliogen Therapeutics, Inc.
  • Patent number: 11542528
    Abstract: Gene therapy compositions and methods are provided that make use of transposases and/or chimeric transposases for targeted transposition, including engineered enzymes and nucleic acids encoding the same. The provided compositions and methods are suitable of treating, for example, an inherited or acquired disease in a patient, as well as treating and/or mitigating a variety of diseases.
    Type: Grant
    Filed: February 11, 2022
    Date of Patent: January 3, 2023
    Assignee: Saliogen Therapeutics, Inc.
    Inventors: Joseph J. Higgins, Scott McMillan, Ray Tabibiazar